Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X:
“Impressive results from a phase 3 trial of Iza-Bren (anti-HER3/EGFR TOPO1 ADC) vs chemo in pretreated mTNBC, with improvement in PFS and OS. High rate of hematologic toxicities, including 5% febrile neutropenia. Phase 3 ongoing to confirm these results in a global population.”
Other articles featuring Paolo Tarantino on OncoDaily.
